Dis-Chem Pharmacies Ltd. said surging demand for GLP-1 medicines is helping drive double-digit growth in its dispensary revenue as South Africans increasingly turn to the expensive drugs used to treat diabetes and obesity.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.